We conducted a placebo-controlled, double-blind study of acyclovir therapy for acute herpes zoster in immunocompromised patients. Of the 94 patients enrolled in the study, 52 had localized skin lesions at entry, and 42 had disseminated cutaneous zoster. A one-week course of intravenous acyclovir (1500 mg per square meter of body-surface area per day) halted progression of zoster in both groups, as determined by development or progression of cutaneous dissemination, development of visceral zoster, or proportion of cases deemed treatment failures. Significantly fewer patients treated with acyclovir within the first three days after the onset of exanthem had complications of zoster, as compared with patients treated with placebo (P = 0.02 by Fisher's exact test), but acyclovir also stopped progression of zoster in patients treated after three days of rash (P = 0.05 by Fisher's exact test). Acyclovir recipients with disseminated cutaneous zoster had a significantly accelerated rate of clearance of virus from vesicles, as compared with placebo recipients (P = 0.05 by the Breslow test).
This article has been cited by other articles:
Nogueira, R. G., Traynor, B.
(2004). The Neurology of Varicella-Zoster Virus: A Historical Perspective. Arch Neurol
61: 1974-1977
[Full Text]
Severson, E. A., Baratz, K. H., Hodge, D. O., Burke, J. P.
(2003). Herpes Zoster Ophthalmicus in Olmsted County, Minnesota: Have Systemic Antivirals Made a Difference?. Arch Ophthalmol
121: 386-390
[Abstract][Full Text]
Acosta, E. P., Balfour, H. H. Jr.
(2001). Acyclovir for Treatment of Postherpetic Neuralgia: Efficacy and Pharmacokinetics. Antimicrob. Agents Chemother.
45: 2771-2774
[Abstract][Full Text]
(2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother
45: 729-748
[Full Text]
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Eysenbach, G., Diepgen, T. L.
(1998). Responses to Unsolicited Patient E-mail Requests for Medical Advice on the World Wide Web. JAMA
280: 1333-1335
[Abstract][Full Text]
Gnann, J. W. Jr., Crumpacker, C. S., Lalezari, J. P., Smith, J. A., Tyring, S. K., Baum, K. F., Borucki, M. J., Joseph, W. P., Mertz, G. J., Steigbigel, R. T., Cloud, G. A., Soong, S.-j., Sherrill, L. C., DeHertogh, D. A., Whitley, R. J.
(1998). Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial. Antimicrob. Agents Chemother.
42: 1139-1145
[Abstract][Full Text]
Hammond, E.
(1987). Herpes-Zoster Infections in Children with Hodgkin's Disease. Journal of Pediatric Oncology Nursing
4: 23-29
Dolin, R
(1985). Antiviral chemotherapy and chemoprophylaxis. Science
227: 1296-1303
[Abstract]
Previous
